Silver Spike Acquisition Corp. Files $250 Million Cannabis SPAC
by Kristi Marvin on 2019-07-22 at 9:15am

On Friday evening, Silver Spike Acquisition Corp. (SSPKU), filed for a $250 million IPO focused on the Cannabis sector. Scott Gordon, who is the founder and Chief Executive Officer of Silver Spike Capital, a newly formed investment platform dedicated to the cannabis industry, will be leading Silver Spike (the SPAC) as CEO and Chairman.

Silver Spike has an interesting name, as do many SPACs (Hedosophia, anyone?), so a quick Google search led me to the “Nevada Silver Spike“. The “Silver Spike” was on of four ceremonial railroad ties that were driven at the connection linking the Central Pacific and the Union Pacific railroads, creating the first transcontinental railroad.  The Iron Spike of the East, the Gold Spike of the West, a hybrid Iron-Silver-Gold Spike, and a Silver Spike to wed them all together.  Maybe this SPAC’s name means something else entirely, but if this is the origin story, it’s rather poetic.  Maybe the Silver Spike SPAC will link the entire country in a Federally legalized cannabis utopia.

Names aside, this SPAC shows a fairly standard $250 million, 1/2 warrant, 24 months structure, which we’ve seen so frequently this year. Nothing fancy. Credit Suisse is on a roll though.  They were recently left lead on both SC Health ($150 million) and Oaktree ($175 million), so Silver Spike, at $250 million, means Credit Suisse has $575 million in total underwritings already for the third quarter.  The league tables should be quite interesting come September.

Additionally, this team doesn’t have any Directors listed yet (should be dropped in in the next filing), but this team looks to have a solid “Street” background.  Mr. Gordon, the CEO and Chairman of Silver Spike, was previously President of Fintech Advisory Inc., an investment manager for a multi-billion dollar family office fund, as well as a Portfolio Manager at Taconic Capital Advisors, among other things. William Healy, President of Silver Spike, was previously President of Pantera Capital Management, an investment management company. The other two team members, Greg Gentile and Mohammed Grimeh, were Chief Executive Officer of GMG Investment Advisors, LLC and deputy Global Head Fixed Income at Millennium Management, respectively.  So this team isn’t just comprised of “weed operators”, they’ve got the financial chops.

Finally, cannabis is hot (smoking hot?). There is undoubtedly going to be tremendous demand for this SPAC and the 1/2 warrant makes this even more palatable.  Look for this one to price mid-August.

Summary of terms below:

Silver Spike terms2

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved